Alpine Immune Sciences Inc
NASDAQ:ALPN
Intrinsic Value
Alpine Immune Sciences, Inc. is a development-stage pharmaceutical company, which engages in the discovery of protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. [ Read More ]
The intrinsic value of one ALPN stock under the Base Case scenario is 4.78 USD. Compared to the current market price of 39.64 USD, Alpine Immune Sciences Inc is Overvalued by 88%.
Valuation Backtest
Alpine Immune Sciences Inc
Run backtest to discover the historical profit from buying and selling ALPN stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Alpine Immune Sciences Inc
Current Assets | 197.4m |
Cash & Short-Term Investments | 193.5m |
Receivables | 900k |
Other Current Assets | 3m |
Non-Current Assets | 43.1m |
Long-Term Investments | 33.5m |
PP&E | 9.2m |
Other Non-Current Assets | 400k |
Current Liabilities | 51.8m |
Accounts Payable | 3.1m |
Accrued Liabilities | 18.7m |
Other Current Liabilities | 30m |
Non-Current Liabilities | 27.1m |
Other Non-Current Liabilities | 27.1m |
Earnings Waterfall
Alpine Immune Sciences Inc
Revenue
|
58.9m
USD
|
Operating Expenses
|
-103.1m
USD
|
Operating Income
|
-44.3m
USD
|
Other Expenses
|
12.1m
USD
|
Net Income
|
-32.2m
USD
|
Free Cash Flow Analysis
Alpine Immune Sciences Inc
What is Free Cash Flow?
ALPN Profitability Score
Profitability Due Diligence
Alpine Immune Sciences Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
Score
Alpine Immune Sciences Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
ALPN Solvency Score
Solvency Due Diligence
Alpine Immune Sciences Inc's solvency score is 78/100. The higher the solvency score, the more solvent the company is.
Score
Alpine Immune Sciences Inc's solvency score is 78/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ALPN Price Targets Summary
Alpine Immune Sciences Inc
According to Wall Street analysts, the average 1-year price target for ALPN is 34.24 USD with a low forecast of 29.29 USD and a high forecast of 46.2 USD.
Ownership
ALPN Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
ALPN Price
Alpine Immune Sciences Inc
Average Annual Return | 45.27% |
Standard Deviation of Annual Returns | 152.69% |
Max Drawdown | -72% |
Market Capitalization | 2.6B USD |
Shares Outstanding | 65 536 000 |
Percentage of Shares Shorted | 11.01% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Alpine Immune Sciences, Inc. is a development-stage pharmaceutical company, which engages in the discovery of protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. The company is headquartered in Seattle, Washington and currently employs 85 full-time employees. The company went IPO on 2015-06-17. The firm is focused on discovering and developing protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. The firm's scientific platform uses a directed evolution process to convert native immune system proteins from the immunoglobulin super family (IgSF) into multi-targeted therapeutics capable of modulating the human immune system. Its product candidates include ALPN-101, ALPN-202 and ALPN-303. ALPN-101 is a dual inducible T cell costimulator (ICOS) and cluster of differentiation 28 (CD28) antagonist intended for the treatment of autoimmune and inflammatory diseases. Its oncology program is ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor intended for the treatment of cancer. ALPN-303 is a dual B-cell cytokine antagonist for the treatment of B-cell mediated diseases.
Contact
IPO
Employees
Officers
The intrinsic value of one ALPN stock under the Base Case scenario is 4.78 USD.
Compared to the current market price of 39.64 USD, Alpine Immune Sciences Inc is Overvalued by 88%.